Single CAR T infusion shows strong response in patients with high-risk smoldering multiple myeloma

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase…

Continue ReadingSingle CAR T infusion shows strong response in patients with high-risk smoldering multiple myeloma